Join
Live feed
·
PRReleasevia Quantisnow
Vor Biopharma Inc. logo

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

ByQuantisnow·Wall Street's wire, on your screen.
VOR· Vor Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VOR (Vor Biopharma Inc.) and more on Quantisnow.